BIOTA Biosciences Recalls Sterile Curcumin Vials Due to Sterility Concerns
BIOTA Biosciences is recalling Sterile Curcumin 50mg/mL vials due to lack of assurance of sterility and the presence of unapproved ingredients.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves a lack of assurance of sterility in a sterile product, which poses a risk of serious injury or death from infection.
Plain-English summary
BIOTA Biosciences LLC is recalling Sterile Curcumin 50mg/mL, 10 mL vials. The recall is due to a lack of assurance of sterility and because the product was marketed without an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA). The product contains unapproved Cannabidiol and Curcumin.
The affected product is distributed nationwide within the United States and in New Zealand. The specific lot numbers involved are 071219CCD, 0712019CCD, and 07122019CCD, with an expiration date of 7/12/2021.
Consumers and healthcare providers should stop using the recalled product and contact their healthcare provider or the recalling firm for further instructions.
The recalled product
- Product
- Sterile Curcumin 50mg/mL, 10 mL vial
- Manufacturer
- BIOTA Biosciences LLC
- Category
- Drug — Sterile Injectable
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot #: 071219CCD
- 0712019CCD
- 07122019CCD
- Exp. Date 7/12/2021
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 5 recalled by BIOTA Biosciences LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 5 products in this recall →Related recalls
Same manufacturer · BIOTA Biosciences LLC
See all →- SevereBiota Biosciences Recalls Sterile Cannabidiol Vials Due to Sterility Concerns
FDA (Drugs) · 2020-07-01
- SevereBIOTA Biosciences Recalls Sterile Curcumin Vials Due to Sterility Concerns
FDA (Drugs) · 2020-07-01
- SevereBIOTA Biosciences Recalls Sterile Cannabidiol and Curcumin Vials
FDA (Drugs) · 2020-07-01
- SevereBIOTA Biosciences Recalls Sterile Cannabidiol Vials for Sterility Concerns
FDA (Drugs) · 2020-07-01
Same hazard · sterility failure
See all →- SevereAvKare Carboxymethylcellulose Sodium Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereAvKare Carboxymethylcellulose Sodium Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereROHTO DIGI-EYE Eye Drops Recalled Over Sterility Assurance Gap
FDA (Drugs) · 2026-07-29
- HighROHTO DRY-AID Eye Drops Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- SevereOne-Piece Introducer Tray kits recalled for sterility failure
FDA (Devices) · 2026-07-22
Similar recalls
- SevereMedaus Recalls GABA 50mg/mL Vials Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls Hydroxy B12 Vials Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls Thiamine Vials Due to Sterility Assurance Concerns
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls Thiamine Vials Due to Lack of Sterility Assurance
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls Methyl B12 Vials Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls Pyridoxal and Thiamine Vials Due to Sterility Concerns
FDA (Drugs) · 2016-07-20